Enclave Advisors’s AbbVie ABBV Stock Holding History

Enclave Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$869K	Sell	3,453 -29	-0.8%	-$6.24K	0.11%	74
2026 Q1	$757K	Buy	3,482 +3	+0.1%	+$665	0.1%	81
2025 Q4	$795K	Sell	3,479 -71	-2%	-$16.2K	0.11%	78
2025 Q3	$822K	Sell	3,550 -7	-0.2%	-$1.43K	0.13%	64
2025 Q2	$660K	Buy	3,557 +235	+7%	+$43.7K	0.11%	65
2025 Q1	$696K	Sell	3,322 -130	-4%	-$25.3K	0.12%	63
2024 Q4	$613K	Buy	3,452 +96	+3%	+$17.6K	0.1%	72
2024 Q3	$663K	Buy	+3,356	New	+$626K	0.11%	70

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Enclave Advisors's ABBV Position: Q2 2026 in Review

Enclave Advisors reduced its AbbVie (ABBV) stake by 0.83% in Q2 2026, selling an estimated $6.24K and leaving 3,453 shares worth $869K. The position accounts for 0.11% of the portfolio, ranked #74.

Enclave Advisors first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Enclave Advisors held 3,453 shares of AbbVie worth $869K as of Q2 2026.
Enclave Advisors sold 29 AbbVie shares in Q2 2026, an estimated $6.24K.
AbbVie made up 0.11% of Enclave Advisors's portfolio in Q2 2026, its #74 holding.
Enclave Advisors first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Enclave Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.